Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression

Immunology and Cell Biology

Volumn 88, Issue 8, 2010, Pages 807-816

  Bhat, Kavita Purnanda ^a   Truax, Agnieszka Dorota ^a   Brooks, Jeanne Kaye ^a   Greer, Susanna Fletcher ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

19S ATPase; 26S proteasome; CIITA; MHC class II; Sug1; transcription regulation

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CD4 ANTIGEN; DNA 26S; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROLINE; PROTEASOME; SERINE; THREONINE; TRANSACTIVATOR PROTEIN; UBIQUITIN;

ADAPTIVE IMMUNITY; ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE; UBIQUITINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MUTAGENESIS, SITE-DIRECTED; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION;

EID: 78649320972     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.45     Document Type: Article

References (70)

1. Matheux F, Villard J. Cellular and gene therapy for major histocompatibility complex class II deficiency. News Physiol Sci 2004; 19: 154-158.
2. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW et al. Tu m o r-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 6047-6055.
3. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000; 20: 6185-6194.
4. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-494.
5. Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 1990; 8: 681-715.
6. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109 (Suppl): S21-S33.
7. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9: 1021-1032.
8. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999; 10: 153-162.
9. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20: 273-277.
10. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 1999; 10: 143-151.
11. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999; 239: 15-27.
12. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
13. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996; 14: 301-331.
14. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-2860.
15. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 2000; 14: 1156-1166.
16. Mahanta SK, Scholl T, Yang FC, Strominger JL. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci USA 1997; 94: 6324-6329.
17. Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, Papamatheakis J. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol 1998; 18: 6777-6783.
18. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 2000; 20: 6051-6061.
19. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
20. Hendil KB, Kristensen P, Uerkvitz W. Human proteasomes analysed with monoclonal antibodies. Biochem J 1995; 305(Pt 1): 245-252.
21. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-847.
22. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 1996; 30: 405-439.
23. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008; 453: 481-488.
24. Lam YA, Lawson TG, Velayutham M, Zweier JL, Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 2002; 416: 763-767.
25. Schreiner P, Chen X, Husnjak K, Randles L, Zhang N, Elsasser S et al. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 2008; 453: 548-552.
26. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160.
27. Makino Y, Yoshida T, Yogosawa S, Tanaka K, Muramatsu M, Tamura TA. Multiple mammalian proteasomal ATPases, but not proteasome itself, are associated with TATA-binding protein and a novel transcriptional activator, TIP120. Genes Cells 1999; 4: 529-539.
28. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 2002; 296: 548-550.
29. Ferdous A, Kodadek T, Johnston SA. A nonproteolytic function of the 19S regulatory subunit of the 26S proteasome is required for efficient activated transcription by human RNA polymerase II. Biochemistry 2002; 41: 12798-12805.
30. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4: 192-201.
31. Rasti M, Grand RJ, Yousef AF, Shuen M, Mymryk JS, Gallimore PH et al. Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription. EMBO J 2006; 25: 2710-2722.
32. Sulahian R, Sikder D, Johnston SA, Kodadek T. The proteasomal ATPase complex is required for stress-induced transcription in yeast. Nucleic Acids Res 2006; 34: 1351-1357.
33. Zhu Q, Wani G, Yao J, Patnaik S, Wang QE, El-Mahdy MA et al. The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter. Oncogene 2007; 26: 4199-4208.
34. Bhat KP, Turner JD, Myers SE, Cape AD, Ting JP, Greer SF. The 19S proteasome ATPase Sug1 plays a critical role in regulating MHC class II transcription. Mol Immunol 2008; 45: 2214-2224.
35. Hegde AN. Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity. Prog Neurobiol 2004; 73: 311-357.
36. Ferdous A, Gonzalez F, Sun L, Kodadek T, Johnston SA. The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. Mol Cell 2001; 7: 981-991.
37. Gillette TG, Gonzalez F, Delahodde A, Johnston SA, Kodadek T. Physical and functional association of RNA polymerase II and the proteasome. Proc Natl Acad Sci USA 2004; 101: 5904-5909.
38. Lassot I, Latreille D, Rousset E, Sourisseau M, Linares LK, Chable-Bessia C et al. The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. Mol Cell 2007; 25: 369-383.
39. Koues OI, Dudley RK, Truax AD, Gerhardt D, Bhat KP, McNeal S et al. Regulation of acetylation at the MHC-II proximal promoter by the 19S proteasomal ATPase Sug1. Mol Cell Biol 2008; 28: 5837-5850.
40. Koues OI, Dudley RK, Mehta NT, Greer SF. The 19S proteasome positively regulates histone methylation at cytokine inducible genes. Biochim Biophys Acta 2009; 1789: 691-701.
41. Truax Agnieszka D, Koues OI, Mentel Marta K, Greer Susanna F. The 19S ATPase S6a (S6¢/TBP1) Regulates Transcription Inititation of the Class II Transactivator. J Mol Biol 2010; 395: 254-269.
42. Fraser RA, Rossignol M, Heard DJ, Egly JM, Chambon P. SUG1, a putative transcrip-tional mediator and subunit of the PA700 proteasome regulatory complex, is a DNA helicase. J Biol Chem 1997; 272: 7122-7126.
43. Rubin DM, Coux O, Wefes I, Hengartner C, Young RA, Goldberg AL, et al. Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature 1996; 379: 655-657.
44. Makino Y, Yamano K, Kanemaki M, Morikawa K, Kishimoto T, Shimbara N et al. SUG1, a component of the 26 S proteasome, is an ATPase stimulated by specific RNAs. J Biol Chem 1997; 272: 23201-23205.
45. Rubin DM, Glickman MH, Larsen CN, Dhruvakumar S, Finley D. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J 1998; 17: 4909-4919.
46. Koues OI, Dudley RK, Truax AD, Gerhardt D, Bhat KP, McNeal S et al. Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1. Mol Cell Biol 2008; 28: 5837-5850.
47. Tosi G, Jabrane-Ferrat N, Peterlin BM. Phosphorylation of CIITA directs its oligomer-ization, accumulation and increased activity on MHCII promoters. EMBO J 2002; 21: 5467-5476.
48. Cressman DE, O'Connor WJ, Greer SF, Zhu X-S, Ting JPY. Mechanisms of nuclear import and export that control the subcellular localization of class ii transactivator. J Immunol 2001; 167: 3626-3634.
49. Drozina G, Kohoutek J, Nishiya T, Peterlin BM. Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histo-compatibility complex class II transcription in macrophages. J Biol Chem 2006; 281: 39963-39970.
50. Tasaki T, Mulder LCF, Iwamatsu A, Lee MJ, Davydov IV, Varshavsky A et al. A family of mammalian e3 ubiquitin ligases that contain the ubr box motif and recognize n-degrons. Mol Cell Biol 2005; 25: 7120-7136.
51. Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM. Expression of MHC II genes. Curr Top Microbiol Immunol 2005; 290: 147-170.
52. Greer SF, Zika E, Conti B, Zhu XS, Ting JP. Enhancement of CIITA transcriptional function by ubiquitin. Nat Immunol 2003; 4: 1074-1082.
53. Archer CT, Burdine L, Liu B, Ferdous A, Johnston SA, Kodadek T. Physical and functional interactions of monoubiquitylated transactivators with the proteasome. J Biol Chem 2008; 283: 21789-21798.
54. Archer CT, Delahodde A, Gonzalez F, Johnston SA, Kodadek T. Activation domain-dependent monoubiquitylation of Gal4 protein is essential for promoter binding in vivo. J Biol Chem 2008; 283: 12614-12623.
55. Mermod N, O'Neill EA, Kelly TJ, Tjian R. The proline-rich transcriptional activator of CTF/NF-I is distinct from the replication and DNA binding domain. Cell 1989; 58: 741-753.
56. Zhou H, Glimcher LH. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 1995; 2: 545-553.
57. Richmond C, Gorbea C, Rechsteiner M. Specific interactions between ATPase subunits of the 26 S protease. J Biol Chem 1997; 272: 13403-13411.
58. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29 (Suppl 1): 3-9.
59. Sisk TJ, Gourley T, Roys S, Chang CH. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J Immunol 2000; 165: 2511-2517.
60. Yee CS, Yao Y, Xu Q, McCarthy B, Sun-Lin D, Tone M et al. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol 2005; 174: 1222-1229.
61. Yee CS, Yao Y, Li P, Klemsz MJ, Blum JS, Chang CH. Cathepsin E: a novel target for regulation by class II transactivator. J Immunol 2004; 172: 5528-5534.
62. Nozell S, Ma Z, Wilson C, Shah R, Benveniste EN. Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J Biol Chem 2004; 279: 38577-38589.
63. Wong AW, Brickey WJ, Taxman DJ, van Deventer HW, Reed W, Gao JX et al. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol 2003; 4: 891-898.
64. Gourley TS, Chang CH. Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J Immunol 2001; 166: 2917-2921.
65. Schnappauf F, Hake SB, Camacho Carvajal MM, Bontron S, Lisowska-Grospierre B, Steimle V. N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur J Immunol 2003; 33: 2337-2347.
66. Truax AD, Koues OI, Mentel MK, Greer SF. The 19S ATPase S6a (S6¢/TBP1) regulates the transcription initiation of class II transactivator. J Mol Biol 2010; 395: 254-269.
67. Chin KC, Li GG, Ting JP. Importance of acidic, proline/serine/threonine- rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc Natl Acad Sci USA 1997; 94: 2501-2506.
68. Fontes JD, Kanazawa S, Jean D, Peterlin BM. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompat-ibility complex class II genes. Mol Cell Biol 1999; 19: 941-947.
69. Fontes JD, Jiang B, Peterlin BM. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res 1997; 25: 2522-2528.
70. Ferdous A, Sikder D, Gillette T, Nalley K, Kodadek T, Johnston SA. The role of the proteasomal ATPases and activator monoubiquitylation in regulating Gal4 binding to promoters. Genes Dev 2007; 21: 112-123.